By Alejandro Fernandez Martell (Lonza)2024-09-10T10:00:58
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-26T13:58:00Z
2026-03-18T14:47:08Z
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2023-09-27T13:56:39
Sponsored by Euretos
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2023-03-07T10:55:58
Sponsored by Agilent
2023-02-07T15:25:20
Sponsored by Bio-Techne
Site powered by Webvision Cloud